<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100043</url>
  </required_header>
  <id_info>
    <org_study_id>3140-23-10-2019</org_study_id>
    <nct_id>NCT05100043</nct_id>
  </id_info>
  <brief_title>Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts</brief_title>
  <official_title>IL-4 and IFN-γ as Immunologic Predictors of Response to HPV Immunotherapy in Warts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study the investigators assessed the invitro role of IL-4 and IFN-γ in&#xD;
      predicting the response to bivalent HPV vaccine after whole blood stimulation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 Patients and 40 controls are enrolled in the study. Participants suffer from chronic&#xD;
      recurrent cutaneous and genital warts. Blood samples were withdrawn then whole blood cultures&#xD;
      are prepared. Cultures are stimulated with bivalent HPVvaccine. IL-4 and IFN-γ measurement in&#xD;
      culture supernatants by ELISA. IL-4 and IFN-γ are investigated to predict the therapeutic&#xD;
      response to bivalent HPV vaccine immunotherapy in warts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2020</start_date>
  <completion_date type="Actual">March 2, 2021</completion_date>
  <primary_completion_date type="Actual">July 3, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of IFN-γ and IL-4 levels</measure>
    <time_frame>48 hours</time_frame>
    <description>Quantitative measurement of IFN-γ and IL-4 in culture supernatants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the size of warts</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical observation and photographing of wart size</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Warts Hand</condition>
  <condition>Wart, Genital</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients having multiple recurrent and recalcitrant cutaneous and genital warts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy volunteers matched for age and sex</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-4 and IFN-γ measurements</intervention_name>
    <description>Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are attendants in Zagazig University Hospitals Dermatology outpatient clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with recurrent and recalcitrant cutaneous and anogenital warts.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to the HPV vaccine&#xD;
&#xD;
          -  Active viral, fungal, or bacterial infections&#xD;
&#xD;
          -  Immunosuppressive diseases or drugs.&#xD;
&#xD;
          -  Autoimmune diseases, or other systemic diseases, e.g., hepatic, or renal disorders,&#xD;
             diabetes, meningitis or convulsions&#xD;
&#xD;
          -  Skin allergies&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Earlier wart treatment at least one month before enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ayman Marei, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Zagazig University , Zagazig, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zagazig University Faculty of Medicine</name>
      <address>
        <city>Zagazig</city>
        <state>Sharkia</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Noha M Hammad, MD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

